AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oyamada, Y.
Right arrow Articles by Wachi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oyamada, Y.
Right arrow Articles by Wachi, M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2006, p. 348-350, Vol. 50, No. 1
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.1.348-350.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Anucleate Cell Blue Assay: a Useful Tool for Identifying Novel Type II Topoisomerase Inhibitors

Yoshihiro Oyamada,1 Hideaki Ito,1* Mika Fujimoto-Nakamura,1 Akihiko Tanitame,2 Noritaka Iwai,3,{dagger} Kazuo Nagai,4 Jun-ichi Yamagishi,1 and Masaaki Wachi3

Pharmacology & Microbiology Research Laboratories,1 Chemical Research Laboratories, Dainippon Pharmaceutical Co., Ltd., Enoki 33-94, Suita, Osaka 564-0053,2 Department of Bioengineering, Tokyo Institute of Technology, 4259 Nagatsuta, Midori-ku, Yokohama 226-8501,3 Department of Biological Chemistry, Chubu University, 1200 Matsumoto, Kasugai, Aichi 487-8501, Japan4

Received 25 July 2005/ Returned for modification 17 September 2005/ Accepted 30 October 2005

About 95,000 compounds were screened by the anucleate cell blue assay. Fifty-one of the hit compounds had various structures and showed inhibitory activity against DNA gyrase and/or topoisomerase IV. Moreover, the compounds exhibited antibacterial activity against a fluoroquinolone- and novobiocin-resistant strain of Staphylococcus aureus. The anucleate cell blue assay is therefore a useful tool for finding novel type II topoisomerase inhibitors.

* Corresponding author. Mailing address: Pharmacology & Microbiology Research Laboratories, Dainippon Pharmaceutical Co., Ltd., Enoki 33-94, Suita, Osaka 564-0053, Japan. Phone: 81-6-63375910. Fax: 81-6-63387656. E-mail: hideaki-ito{at}ds-pharma.co.jp.

{dagger} Present address: Frontier Collaborative Research Center, Tokyo Institute of Technology, 4259 Nagatsuta, Midori-ku, Yokohama 226-8501, Japan.

Antimicrobial Agents and Chemotherapy, January 2006, p. 348-350, Vol. 50, No. 1
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.1.348-350.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2006 by the American Society for Microbiology. All rights reserved.